Debug Stats | ### Total Build Time: 17 ms 32.849 KB CONCEPT_NAME gt=1 ms Completed: 1 ms rowSize= 372 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 318 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=9 ms Completed: 9 ms rowSize= 14.670 KBCONCEPT_GENES gt=4 ms Completed: 4 ms rowSize= 16.264 KBCONCEPT_XREFS gt=3 ms Completed: 3 ms rowSize= 1.171 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Relationships (28)
Relation Types: diso_to_anat : 21 diso_to_diso : 7
Relationships: is_abnormal_cell_of_disease : 6 is_associated_anatomic_site_of : 2 is_finding_of_disease : 2 is_normal_cell_origin_of_disease : 4 is_normal_tissue_origin_of_disease : 2 is_not_abnormal_cell_of_disease : 2 is_not_finding_of_disease : 1 is_not_normal_cell_origin_of_disease : 3 is_primary_anatomic_site_of_disease : 2 isa : 3 may_be_finding_of_disease : 1 | |
DISO_to_ANAT | | is_abnormal_cell_of_disease |
Atypical lymphocyte C0221277 | DISO_to_ANAT | | is_not_normal_cell_origin_of_disease |
B lymphoblast C1516097 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
B-Lymphocytes C0004561 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Cancer Cell C0334227 | DISO_to_ANAT | | is_not_abnormal_cell_of_disease |
Cells, Reed-Sternberg C0085133 | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
HEMOLYMPHORETICULAR TISSUE C1512398 | DISO_to_ANAT | | is_associated_anatomic_site_of |
Hematopoietic and Lymphatic System C1512394 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Hematopoietic and Lymphoid Cell C1512385 | DISO_to_ANAT | | is_associated_anatomic_site_of |
Integumentary System C0037267 | DISO_to_ANAT | | is_primary_anatomic_site_of_disease |
Lymphatic System C0024235 | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
Lymphatic Tissue C0024296 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Lymphocyte C0024264 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Mature B-Cell C1513019 | DISO_to_ANAT | | is_not_normal_cell_origin_of_disease |
Myeloid Cells C0887899 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic B-Lymphocyte C1513929 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Cell C0597032 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Hematopoietic and Lymphoid Cell C1513983 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Lymphocyte C1514011 | DISO_to_ANAT | | is_not_abnormal_cell_of_disease |
Neoplastic T-Lymphocyte and Neoplastic Natural Killer Cell C1514110 | DISO_to_ANAT | | is_not_normal_cell_origin_of_disease |
Plasma Cells C0032112 | DISO_to_ANAT | | is_primary_anatomic_site_of_disease |
Skin C1123023 | DISO_to_DISO | | isa |
C-MALT C1367653 | DISO_to_DISO | | is_finding_of_disease |
Cutaneous Involvement C1511567 | DISO_to_DISO | | may_be_finding_of_disease |
Cutaneous Nodule C0037287 | DISO_to_DISO | | is_not_finding_of_disease |
Favorable Clinical Outcome C1333602 |
|
Genes (8)
Species: human : 8 | |
Human | MALT1 | 10892 | mucosa associated lymphoid tissue lymphoma translocation gene 1 | Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. | Human | CXCL13 | 10563 | chemokine (C-X-C motif) ligand 13 | We analysed the immunophenotypic and molecular expression of BCA-1 (B-cell-specific chemokine) and CXCR5 (BCA-1 receptor) in normal skin and different cutaneous lymphoproliferative disorders (cutaneous T-cell lymphoma (CTCL); cutaneous B-cell lymphoma (CBCL); cutaneous B-cell pseudolymphoma (PCBCL)), with the aim of investigating their possible involvement in the pathogenesis of cutaneous B-cell disorders. | Human | TCL1A | 8115 | T-cell leukemia/lymphoma 1A | In B-cell neoplasia, TCL1 was expressed in the majority of the cases, including lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (60%), and primary cutaneous B cell lymphoma (55%). | Human | NFKB2 | 4791 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) | In the present study we investigated the pathogenetic role of c-myc, bcl-2, and lyt-10 oncogenes, bcl-1 locus, and p53 suppressor gene in a representative panel of cutaneous lymphomas, including 25 cases of cutaneous B cell lymphoma (CBCL) and 29 cases of cutaneous T cell lymphoma (CTCL). | Human | JUNB | 3726 | jun B proto-oncogene | Twenty-four percent of cases, including 7 of 10 cases of primary cutaneous CD30(+) anaplastic large-cell lymphoma (C-ALCL), 4 of 14 MF, 4 of 22 SS, and 2 of 23 primary cutaneous B-cell lymphoma (PCBCL) showed amplification of JUNB, and high-level amplification of this oncogene was present in 3 C-ALCL and 2 MF cases. METHODS: We analysed gene copy number of BCL2 and JUNB in 88 DNA samples from 80 patients with PCL consisting of Sézary syndrome/mycosis fungoides (SS/MF), primary cutaneous B-cell lymphoma (PCBCL) and primary cutaneous CD30+ anaplastic large cell lymphoma (C-ALCL) by the use of real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC). | Human | IL7R | 3575 | interleukin 7 receptor | No expression of IL-7R was observed in cutaneous B-cell lymphomas, benign cutaneous lymphoid infiltrates, and reactive lymph nodes. | Human | CDKN2B | 1030 | cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | In primary cutaneous B cell lymphomas with allelic loss or promotor hypermethylation of either p15 or p16, loss of expression in tumor cells was identified in 5 of 8 and 9 of 10 cases, respectively. We analyzed DNA from 36 cases of primary cutaneous B cell lymphomas, four systemic B cell lymphomas, and six benign B cell lymphoproliferative infiltrates for abnormalities of p15 and p16 using microsatellite markers for 9p21, methylation specific polymerase chain reaction, and polymerase chain reaction/single stranded conformational polymorphism analysis with exon specific primers. | Human | MS4A1 | 931 | membrane-spanning 4-domains, subfamily A, member 1 | Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). As cutaneous B-cell lymphoma (CBCL) also expresses the CD20 molecule, three patients with histologically and immunohistochemically confirmed CBCL without systemic involvement were treated with low-dose intralesional rituximab in a pilot study. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. Although primary cutaneous B-cell lymphomas (PCBCL) also express the CD20 antigen, relatively few reports of rituximab use in PCBCL have been published to date. CONCLUSIONS: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase. A new humanized anti CD20-antibody can be used for patients with cutaneous B-cell lymphomas, expressing the B-cell antigen CD20 in most of the cases. We describe a patient with widespread cutaneous B-cell lymphoma who was treated successfully with a recently approved chimeric monoclonal antibody directed against the CD20 antigen (rituximab) and the CD20-negative relapse that resulted. |
|